Advertisement covers the 17th Conference on Retroviruses and Opportunistic Infections

Thai Vaccine Trial Shows Minimal Benefit

Winter/Spring 2010

The ALVAC/AIDSVAX prime-boost combination HIV vaccine demonstrated a small and only marginally significant protective effect in the Phase III RV144 clinical trial in Thailand. While detailed data did not live up to the initial hype, some researchers hailed the findings as proof-of-concept that a preventive HIV vaccine can work.

In September, the U.S. Military HIV Research Program (MHRP) announced that in an analysis of more than 16,000 study participants, those who received ALVAC/AIDSVAX had a 31% lower risk of HIV infection compared with placebo recipients. However, a closer look at the complete data, presented at the AIDS Vaccine 2009 conference in Paris and simultaneously published in the October 20, 2009, online edition of the New England Journal of Medicine, revealed less impressive results.

Overall, 56 vaccine recipients and 76 placebo recipients were newly infected with HIV during follow-up. In an intent-to-treat analysis, there was a trend toward a significant protective effect, with an efficacy of 26.4%; however, the P value (a standard statistical measure) of 0.08 did not reach the usual 0.05 cut-off for significance and the confidence interval was very wide, indicating considerable uncertainty about whether the results were due to chance alone.

In a modified intent-to-treat analysis that excluded seven people who were belatedly determined to have been already HIV-infected at study entry, vaccine efficacy was 31.2% -- the figure reported in September -- and this just reached the cut-off for statistical significance, with a P value of 0.04. But in a per-protocol or as-treated analysis of participants who received all vaccine doses as scheduled, efficacy fell to 26.2% and was no longer close to borderline significance (P = 0.16). Vaccination did not affect viral load levels or CD4 cell counts in participants who did become infected.

"Although the results show only a modest benefit, they offer insight for future research," the RV144 investigators concluded. For example, they plan to explore why ALVAC/AIDSVAX provided the greatest protective effect during the first year (about a 60% risk reduction), and why heterosexual participants at low or medium risk for HIV infection appeared to derive more benefit than high-risk participants such as gay men or injection drug users.

The Thai trial results were "the first signal of [HIV vaccine] efficacy, extremely modest though it might be," National Institute of Allergy and Infectious Diseases director Anthony Fauci said at a CROI plenary. In particular, the findings may offer insights about the correlates of protection, or what needs to happen for a vaccine to work.

Liz Highleyman ( is a freelance medical writer based in San Francisco.

This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
See Also
Investigational Vaccine Shows Modest Potential for Protecting Against HIV Infection
Basic Information on the RV144 Phase III HIV Vaccine Trial
HIV Vaccine Study First to Show Some Effectiveness in Preventing HIV (Press Release From U.S. Military HIV Research Program)

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.